- Home
- CDXC
CDXC
ChromaDex Corporation
as 07-26-2024 4:00pm EST
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | LOS ANGELES |
| Market Cap: | N/A | IPO Year: | N/A |
| Target Price: | $6.00 | AVG Volume (30 days): | 628.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.05 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.25 - $4.65 | Next Earning Date: | 08-07-2024 |
| Revenue: | $83,167,000 | Revenue Growth: | 7.52% |
| Revenue Growth (this year): | 18.38% | Revenue Growth (next year): | 17.18% |
Latest ChromaDex Corporation News
CDXC Breaking Stock News: Dive into CDXC Ticker-Specific Updates for Smart Investing
Business Wire
2 days ago
ChromaDex to Report Second Quarter 2024 Financial Results on Wednesday, August 7, 2024
Business Wire
3 days ago
ChromaDex Launches Niagen+ NAD+ Test Kit Available Exclusively to Health Care Practitioners (HCPs)
Business Wire
4 days ago
ChromaDex Appoints Carlos Lopez as Senior Vice President, General Counsel
Business Wire
10 days ago
ChromaDex Announces Pharmaceutical-Grade Intravenous and Injectable Niagen® Will Debut at Leading Wellness Clinics in August
Simply Wall St.
14 days ago
When Will ChromaDex Corporation (NASDAQ:CDXC) Turn A Profit?
MT Newswires
25 days ago
ChromaDex Joins Russell 2000 Index
Business Wire
25 days ago
ChromaDex to Join Russell 2000® Index
MT Newswires
a month ago
ChromaDex Chief Financial Officer Brianna Gerber to Resign
Compare CDXC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CDXC ChromaDex Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.